New CAR-T therapy targets Hard-to-Treat solid tumors
NCT ID NCT04503278
First seen Nov 19, 2025 · Last updated May 24, 2026 · Updated 29 times
Summary
This early-phase trial tests a new treatment for people with advanced solid tumors that have not responded to standard therapy. The treatment uses specially engineered immune cells (CAR-T cells) designed to find and attack cancer cells that carry a protein called CLDN6. Some participants also receive an RNA vaccine to boost the CAR-T cells. The main goal is to check safety and find the best dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Charité - Universitätsmedizin Berlin - Campus Benjamin Franklin
RECRUITINGBerlin, 12200, Germany
-
Erasmus MC - Universitair Medisch Centrum - Medical oncology
RECRUITINGRotterdam, 3015, Netherlands
-
He Nederlands Kanker Instituut (The Netherlands Cancer Institute) - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)
RECRUITINGAmsterdam, 1066, Netherlands
-
Karolinska Comprehensive Cancer Center Cancerstudieenheten Huddinge Karolinska Universitetssjukhuset
RECRUITINGStockholm, 14186, Sweden
-
Medizinische Hochschule Hannover - Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation
RECRUITINGHanover, 30625, Germany
-
Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg
RECRUITINGHeidelberg, 69120, Germany
-
Peter MacCallum Cancer Centre
COMPLETEDMelbourne, Victoria, 3000, Australia
-
Universitätsklinikum Erlangen - Hämatologie & Intrinsische Onkologie - Medizinische Klinik 5
RECRUITINGErlangen, 91054, Germany
-
Universitätsklinikum Hamburg Eppendorf - II Medizinische Klinik und Poliklinik
RECRUITINGHamburg, 20246, Germany
-
Universitätsklinikum Köln AÖR-Centrum für Integrierte Onkologie (CIO)-Studienzentrum der Klinik I für Innere Medizin (CTU Cologne)
RECRUITINGCologne, 50937, Germany
-
Universitätsklinikum Regensburg - Klinik und Poliklinik für Innere Medizin III
RECRUITINGRegensburg, 93053, Germany
-
Universitätsmedizin Mainz - III Medizinische Klinik und Poliklinik
RECRUITINGMainz, 55131, Germany
Conditions
Explore the condition pages connected to this study.